Anika Therapeutics Company Leadership
| ANIK Stock | USD 15.42 0.20 1.28% |
Anika Therapeutics employs about 288 people. The company is managed by 14 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 20.57 employees per reported executive. Inspection of Anika Therapeutics' management performance can provide insight into the company performance.
| Cheryl Blanchard Director Independent Director |
Anika |
Anika Therapeutics' latest congressional trading
Congressional trading in companies like Anika Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Anika Therapeutics by those in governmental positions are based on the same information available to the general public.
| 2021-03-05 | Representative Tom Malinowski | Acquired Under $15K | Verify |
Anika Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0482) %, meaning that it created substantial loss on money invested by shareholders. Anika Therapeutics' management efficiency ratios could be used to measure how well Anika Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Anika Therapeutics Workforce Comparison
Anika Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 9,208. Anika Therapeutics holds roughly 288 in number of employees claiming about 3% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.47) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Anika Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anika Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anika Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Anika Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Colleran 3 days ago Acquisition by David Colleran of 13669 shares of Anika Therapeutics subject to Rule 16b-3 | ||
Cheryl Blanchard over a week ago Disposition of 20002 shares by Cheryl Blanchard of Anika Therapeutics subject to Rule 16b-3 | ||
David Colleran over two months ago Acquisition by David Colleran of 7662 shares of Anika Therapeutics subject to Rule 16b-3 | ||
Anne Nunes over three months ago Disposition of 2491 shares by Anne Nunes of Anika Therapeutics subject to Rule 16b-3 | ||
Anne Nunes over three months ago Disposition of 2491 shares by Anne Nunes of Anika Therapeutics subject to Rule 16b-3 | ||
David Colleran over six months ago Disposition of 1081 shares by David Colleran of Anika Therapeutics at 26.91 subject to Rule 16b-3 | ||
Capper Joseph H over six months ago Acquisition by Capper Joseph H of 5771 shares of Anika Therapeutics subject to Rule 16b-3 | ||
Griffin Stephen D. over six months ago Disposition of tradable shares by Griffin Stephen D. of Anika Therapeutics subject to Rule 16b-3 |
Anika Therapeutics Notable Stakeholders
An Anika Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Anika Therapeutics often face trade-offs trying to please all of them. Anika Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Anika Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Stephen Griffin | CFO VP | Profile | |
| Cheryl Blanchard | Independent Director | Profile | |
| Ian McLeod | VP Officer | Profile | |
| David JD | General VP | Profile | |
| James Chase | Senior Marketing | Profile | |
| Bart Bracy | VP Americas | Profile | |
| Lisa Funiciello | Vice Resources | Profile | |
| Mark Namaroff | Executive Communications | Profile | |
| Michael CPA | Executive Officer | Profile | |
| Charles III | VP Counsel | Profile | |
| Michael Levitz | Executive Officer | Profile | |
| Ben Joseph | Vice Development | Profile | |
| Anne Nunes | VP Operations | Profile | |
| David Colleran | Gen VP | Profile |
About Anika Therapeutics Management Performance
The success or failure of an entity such as Anika Therapeutics often depends on how effective the management is. Anika Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Anika management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Anika management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 297 people.
Anika Therapeutics Workforce Analysis
Traditionally, organizations such as Anika Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Anika Therapeutics within its industry.Anika Therapeutics Manpower Efficiency
Return on Anika Therapeutics Manpower
| Revenue Per Employee | 416.3K | |
| Revenue Per Executive | 8.6M | |
| Net Loss Per Employee | 195.8K | |
| Net Loss Per Executive | 4M | |
| Working Capital Per Employee | 313.7K | |
| Working Capital Per Executive | 6.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.